Matritech (NASDAQ - NMPS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matritech (NASDAQ - NMPS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Damon Pham who wrote (348)	1/23/1997 1:09:00 AM
From: Miles Rhyne Hoffman, CFA	of 849

Zacks expects -7 vs -7 on 2/7. Hey, don't "ya'll" believe the NMP22 test kit should be a strong winner alone, not to mention the product pipeline? I thank God for this product JUST IN CASE I ever have to be tested, ie who would want a cystoscopy? The 3rd qtr is hard to judge because the kit was just approved for the US in June 1996... "Revenues from product sales in the third quarter of 1996 were $484,000, compared with $97,000 in the corresponding quarter of 1995 due to worldwide sales of the Company's NMP22(R) Test Kit for bladder cancer, which was approved for sale in the United States in July 1996." Anyone got a clue as to the US vs non-US breakdown of these sales? Miles PS: Rechecking what I know about this company, briefly scanning Yahoo news and the company's shareholder info I received, convinced me to double my position under $8/sh.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next